Featured Research

from universities, journals, and other organizations

Drug trial shows promise for treating constipation caused by pain medicines

Date:
June 4, 2014
Source:
University of Michigan Health System
Summary:
Taking medicines for chronic pain can often lead to constipation, but a study shows a daily pill can get things moving again. Globally, approximately 28 million to 35 million, or nearly half, of patients taking opioids for long-term pain develop constipation. Patients get sub-optimal results from laxatives.

Pain medicines often lead to constipation for patients seeking long-term pain relief, but an investigational once-daily drug may help, according to study led by the University of Michigan Health System.

Globally, approximately 28 million to 35 million, or nearly half, of patients taking opioids for long-term pain develop constipation. Patients get sub-optimal results from laxatives.

The results of two pivotal Phase 3 studies -- KODIAC-4 and KODIAC-5 of naloxegol, an investigational treatment for opioid-induced constipation (OIC) -- were published online first in the New England Journal of Medicine.

A 25 mg dose of the investigational drug naloxegol safely increased bowel movements among opioid-induced constipation sufferers, compared to a placebo, and the effects were maintained over a 12-week treatment period.

"The studies showed rapid and sustained improvement for these patients, without compromising their pain management," says lead study author and gastroenterologist William Chey, M.D., professor of internal medicine at the U-M Health System.

Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist, which has been specifically designed for the treatment of opioid-induced constipation (OIC), a common and often debilitating side effect of prescription medicines used to treat osteoarthritis and chronic back pain.

Opioids play an important role in chronic pain relief by binding to mu-receptors in the brain, blocking the brain's ability to perceive brain. But they also bind to mu-receptors in the bowel, contributing to constipation.

Naloxegol is designed to block the binding of opioids to receptors in the gastrointestinal tract without impacting the opioid receptors in the brain.

The Phase 3 studies enrolled 652 people in one trial and 700 in another. The 12-week, multicenter, randomized, double blind, placebo-controlled pivotal trials evaluated 12.5 mg and 25 mg doses of naloxegol, once-daily.

The most commonly reported adverse effects with naloxegol were abdominal pain, diarrhea, nausea, vomiting, flatulence and appeared to be dose-ordered, occurring more commonly in the 25 mg group.

Most adverse events were mild to moderate in severity and occurred shortly after initiation of naloxegol. There was one major cardiovascular adverse event in the 25 mg treatment group, one in the 12.5 mg treatment group and two among those in the placebo group.


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. William D. Chey, Lynn Webster, Mark Sostek, Jaakko Lappalainen, Peter N. Barker, Jan Tack. Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain. New England Journal of Medicine, 2014; 140604140030004 DOI: 10.1056/NEJMoa1310246

Cite This Page:

University of Michigan Health System. "Drug trial shows promise for treating constipation caused by pain medicines." ScienceDaily. ScienceDaily, 4 June 2014. <www.sciencedaily.com/releases/2014/06/140604202102.htm>.
University of Michigan Health System. (2014, June 4). Drug trial shows promise for treating constipation caused by pain medicines. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2014/06/140604202102.htm
University of Michigan Health System. "Drug trial shows promise for treating constipation caused by pain medicines." ScienceDaily. www.sciencedaily.com/releases/2014/06/140604202102.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins